Pixium Vision

What is Pixium Vision?

Pixium Vision, established in Paris in November 2011, is an investment fund focused on the development of innovative retinal implant systems for patients who have lost their vision, aiming to enhance their sight capabilities to allow for a more independent lifestyle. They are leveraging advancements in neural processing, microelectronics, and computing.

Their inaugural device, the IRIS1 (Intelligent Retinal Implant System), an epi-retinal implant placed on the retinal surface, is presently undergoing clinical trials to acquire the CE Mark. Following IRIS1, Pixium is working on the next-generation system, IRIS2, which is anticipated to offer improved visual acuity and incorporates several technological enhancements.

Beyond these, Pixium is developing the sub-retinal implant system IRIS3, which promises to significantly better the visual performance compared to its predecessors, potentially approaching the vision of normal, healthy eyes. Pixium's origins are as a spin-out from the Vision Institute and Université Pierre et Marie Curie, involving collaboration with several prominent European academic teams.

It's supported by a consortium of leading European venture capital firms such as Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Seventure, and Polytechnos.

Since its inception, Pixium Vision SA's assets have been acquired by Science Corporation, which includes ongoing late-stage clinical trials for macular degeneration. Science Corporation now sponsors the European clinical trials and is the legal manufacturer for the PRIMA device.